Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
NCT01278745 · National Institute of Allergy and Infectious Diseases (NIAID) · PHASE2 · terminated · last registry update 2026-09-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to inability to meet accrual goals within the funding period” | – | Registry record, National Institute of Allergy and Infectious Diseases (NIAID) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IMPDH1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Phase 3 first posted: Chinese PLA General Hospital, Secukinumab + Mycophenolate mofetil (MMF) (NCT07917247)
- 2026-10-29Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Donor-derived Mesenchymal Stromal Cells + alemtuzumab (NCT03504241)
- 2026-10-15Results posted on the registry: Rohit Aggarwal, MD, Nintedanib + Placebo (NCT05799755)
- 2026-10-15Also stopped (withdrawn): Brigham and Women's Hospital, a drug against IMPDH1 (NCT02741102)
- 2026-09-29Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), tocilizumab + Placebo (NCT03644667)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Belatacept + methylprednisolone (NCT01790594)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Tacrolimus (CNI) Withdrawal + Standard Immunosuppressive Therapy (NCT01517984)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Alemtuzumab + MMF (NCT01436305)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Anti-thymocyte Globulin (Rabbit) + belatacept (NCT01856257)
- 2026-09-18Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Cyclosporin + Mycophenolate mofetil and Dexamethasone (NCT00135811)
- 2026-09-10Also stopped (suspended): Leland Metheny, Cyclophosphamide + Fludarabine (NCT06680661)
- 2026-09-03Also stopped (withdrawn): Mayo Clinic, Axatilimab + Cyclophosphamide (NCT07349771)
- 2026-08-17Phase 3 first posted: Zhao Minghui, obinutuzumab (RO5072759) (NCT07767188)
- 2026-07-31Results posted on the registry: Boston Children's Hospital, Everolimus + Tacrolimus (NCT03386539)
- 2026-07-23Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Cyclophosphamide + Tacrolimus (NCT03712878)
- 2026-07-21Results posted on the registry: Children's Hospital of Philadelphia, Reduced-Intensity Conditioning (NCT01050855)
- 2026-07-08Phase 3 first posted: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Methotrexate + Anti-CD25 Monoclonal Antibody (NCT07689630)
- 2026-06-10Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Moderna mRNA-1273 + BNT162b2 (NCT05000216)
- 2026-06-01Results posted on the registry: Washington University School of Medicine, Tacrolimus + Mycophenolate mofetil (NCT02782546)
- 2026-06-01Results posted on the registry: Fred Hutchinson Cancer Center, Cyclophosphamide + Fludarabine Phosphate (NCT02220985)
- 2026-05-29Results posted on the registry: National Cancer Institute (NCI), Mycophenolate Mofetil + Tacrolimus (NCT05907746)
- 2026-05-27Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Fludarabine + Busulfan (NCT01135329)
- 2026-05-26Results posted on the registry: Memorial Sloan Kettering Cancer Center, Cyclosporine + Mycophenolate Mofetil (NCT03434730)
- 2026-05-26Phase 3 first posted: Alliance for Clinical Trials in Oncology, Temozolomide (TMZ) + Mycophenolate Mofetil (NCT07605364)
- 2026-05-14Results posted on the registry: University of Michigan Rogel Cancer Center, Mycophenolate Mofetil + Temozolomide (NCT04477200)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision